HIMX [Himax Technologies] SC 13G/A: SCHEDULE 13G CUSIP No. 43289P106 2 9 Page
[SCHEDULE 13G CUSIP No. 43289P106 2 9 Page]
[SCHEDULE 13G CUSIP No. 43289P106 2 9 Page]
[FORM 10-Q (Mark One) x For the quarterly period ended December 31, 2013 o For the transition period from _______________ to _______________ Tianyin Pharmaceutical Co., Inc. Delaware (State or other jurisdiction of incorporation or organization) Identification No.) 23rd Floor, Unionsun Yangkuo Plaza No. 2, Block 3, Renmin Road South Chengdu, P. R. China, 610041 +0086-028-86154737 (Address, including zip code, and] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER I, Guoqing Jiang certify that: 1. I have reviewed this quarterly report on Form 10-Q for the period ended December 31, 2013 of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make] [CERTIFICATION OF CHIEF FINANCIAL OFFICER I, James Jiayuan Tong, certify that: 1. I have reviewed this quarterly report on Form 10-Q for the period ended December 31, 2013 of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Guoqing Jiang Chief Executive Officer, Chief Accounting Officer, Chairman EX-32.1 4 f10q1213ex32i_tianyinphar.htm CERTIFICATION] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. James Jiayuan Tong Chief Financial Officer, Director EX-32.2 5 f10q1213ex32ii_tianyinphar.htm CERTIFICATION]
[(Name of Issuer) AMERICAN DEPOSITARY RECEIPTS (Title of Class of Securities) 74906P104 (CUSIP Number) December 31, 2013 (Date of Event which Requires Filing of Statement) [x] Rule 13d – 1(b) [ ] Rule 13d – 1(c) [ ] Rule 13d – 1(d) * The remainder of this cover page shall be filled out for a reporting person’s initial filing on]
[New York Menlo Park Washington DC São Paulo London Paris Madrid Tokyo Beijing Hong Kong Li He LLP Davis Polk & Wardwell 2201 China World Office 2 1 Jian Guo Men Wai Avenue Chaoyang District Beijing 100004 86 10 8567 5005 tel 86 10 8567 5105 fax li.he@davispolk.com February 14, 2014 iKang Guobin Healthcare Group, Inc. Draft Registration Statement on]
[Joint Filing Agreement Yongqiang Qian Yongqiang Qian Fame Gain Investments Limited Yongqiang Qian Director EX-99.1 2 a14-5098_3ex99d1.htm EX-99.1] [CUSIP No. 477374 102 1. Names of Reporting Persons]
[Item 1: Reporting Person - FMR LLC Item 4: Delaware Item 5: 1,807,013 Item 6: 0 Item 7: 2,619,093 Item 8: 0 Item 9: 2,619,093 Item 11: 5.159% Item 12: HC Cusip #836034926 Item 1: Reporting Person - Edward C. Johnson 3d Item 5: 0 Item 6: 0 Item 7: 2,619,093 Item 8: 0 Item 9: 2,619,093 Item 11: 5.159%]
[Oberweis Asset Management, Inc. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) Not Applicable (a) o (b) o 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Illinois NUMBER OF 5 SOLE VOTING POWER None SHARES BENEFICIALLY OWNED BY 6 SHARED VOTING POWER 1,259,344 ADSs* EACH REPORTING PERSON 7 SOLE DISPOSITIVE POWER None WITH]
[Form 6-K TABLE OF CONTENTS Page 3 Announcement on the Performance of Undertakings by the Related Parties 4 2 SINOPEC SHANGHAI PETROCHEMICAL COMPANY LIMITED]